Shares of Adma Biologics (ADMA) have gained 20.7% over the past four weeks to close the last trading session at $19.04, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25 indicates a potential upside of 31.3%.The mean estimate comprises four short-term price targets with a standard deviation of $0.82. While the lowest estimate of $24 indicates a 26.1% increase from the current ...